CN116370485B - Application of 2-hydroxyphenyl alpha-D-glucopyranoside in preparation of medicine for treating osteoporosis - Google Patents
Application of 2-hydroxyphenyl alpha-D-glucopyranoside in preparation of medicine for treating osteoporosis Download PDFInfo
- Publication number
- CN116370485B CN116370485B CN202310482744.0A CN202310482744A CN116370485B CN 116370485 B CN116370485 B CN 116370485B CN 202310482744 A CN202310482744 A CN 202310482744A CN 116370485 B CN116370485 B CN 116370485B
- Authority
- CN
- China
- Prior art keywords
- glucopyranoside
- hydroxyphenyl
- alpha
- bone
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- NMZWIAATAZXMRV-ZIQFBCGOSA-N (2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-(2-hydroxyphenoxy)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC1=CC=CC=C1O NMZWIAATAZXMRV-ZIQFBCGOSA-N 0.000 title claims abstract description 71
- 239000003814 drug Substances 0.000 title claims abstract description 17
- 208000001132 Osteoporosis Diseases 0.000 title claims abstract description 8
- 238000002360 preparation method Methods 0.000 title abstract description 7
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 47
- 230000001737 promoting effect Effects 0.000 claims abstract description 19
- 210000002889 endothelial cell Anatomy 0.000 claims abstract description 12
- 230000014509 gene expression Effects 0.000 claims abstract description 11
- 238000013508 migration Methods 0.000 claims abstract description 10
- 230000017423 tissue regeneration Effects 0.000 claims abstract description 10
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 9
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 8
- 238000011069 regeneration method Methods 0.000 claims abstract description 8
- 230000009471 action Effects 0.000 claims abstract description 6
- 230000008929 regeneration Effects 0.000 claims abstract description 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 4
- 230000002491 angiogenic effect Effects 0.000 claims description 4
- 230000004663 cell proliferation Effects 0.000 claims description 4
- 230000012292 cell migration Effects 0.000 claims description 3
- 101100263837 Bovine ephemeral fever virus (strain BB7721) beta gene Proteins 0.000 claims 1
- 101100316840 Enterobacteria phage P4 Beta gene Proteins 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 abstract description 13
- 210000003606 umbilical vein Anatomy 0.000 abstract description 11
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 9
- 230000035755 proliferation Effects 0.000 abstract description 8
- 210000004369 blood Anatomy 0.000 abstract description 7
- 239000008280 blood Substances 0.000 abstract description 7
- 230000005012 migration Effects 0.000 abstract description 7
- 230000008439 repair process Effects 0.000 abstract description 5
- 230000001172 regenerating effect Effects 0.000 abstract description 2
- 230000000694 effects Effects 0.000 description 18
- 241000699670 Mus sp. Species 0.000 description 14
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 210000000689 upper leg Anatomy 0.000 description 8
- 210000004204 blood vessel Anatomy 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 210000001519 tissue Anatomy 0.000 description 7
- 230000001054 cortical effect Effects 0.000 description 6
- 239000000178 monomer Substances 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 230000011164 ossification Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- -1 (2S, 3R,4S,5R, 6R) -6- (acetoxymethyl) tetrahydro-2H-pyran-2, 3,4, 5-tetraacetic acid Chemical compound 0.000 description 4
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 4
- 108010082126 Alanine transaminase Proteins 0.000 description 4
- 102000004420 Creatine Kinase Human genes 0.000 description 4
- 108010042126 Creatine kinase Proteins 0.000 description 4
- 210000001015 abdomen Anatomy 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000007943 implant Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000010883 osseointegration Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 238000010603 microCT Methods 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 210000003101 oviduct Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 210000003556 vascular endothelial cell Anatomy 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000005156 Dehydration Diseases 0.000 description 2
- 229930040373 Paraformaldehyde Natural products 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 210000002449 bone cell Anatomy 0.000 description 2
- 230000010256 bone deposition Effects 0.000 description 2
- 230000004097 bone metabolism Effects 0.000 description 2
- DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 2
- YCIMNLLNPGFGHC-UHFFFAOYSA-N catechol Chemical compound OC1=CC=CC=C1O YCIMNLLNPGFGHC-UHFFFAOYSA-N 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000007405 data analysis Methods 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 230000010595 endothelial cell migration Effects 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 210000004349 growth plate Anatomy 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 229960002378 oftasceine Drugs 0.000 description 2
- 210000001672 ovary Anatomy 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 229920002866 paraformaldehyde Polymers 0.000 description 2
- 201000001245 periodontitis Diseases 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000002110 toxicologic effect Effects 0.000 description 2
- 231100000759 toxicological effect Toxicity 0.000 description 2
- 229940126680 traditional chinese medicines Drugs 0.000 description 2
- 210000004291 uterus Anatomy 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- ORZHVTYKPFFVMG-UHFFFAOYSA-N xylenol orange Chemical compound OC(=O)CN(CC(O)=O)CC1=C(O)C(C)=CC(C2(C3=CC=CC=C3S(=O)(=O)O2)C=2C=C(CN(CC(O)=O)CC(O)=O)C(O)=C(C)C=2)=C1 ORZHVTYKPFFVMG-UHFFFAOYSA-N 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 description 1
- 238000005160 1H NMR spectroscopy Methods 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 241000213006 Angelica dahurica Species 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- XLYOFNOQVPJJNP-ZSJDYOACSA-N Heavy water Chemical compound [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 1
- 241000251511 Holothuroidea Species 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 108010087230 Sincalide Proteins 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 108090000340 Transaminases Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 210000000593 adipose tissue white Anatomy 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 229940107666 astragalus root Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 230000018678 bone mineralization Effects 0.000 description 1
- 230000010072 bone remodeling Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 208000001277 chronic periodontitis Diseases 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000029578 entry into host Effects 0.000 description 1
- 210000003195 fascia Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000013230 female C57BL/6J mice Methods 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000003456 ion exchange resin Substances 0.000 description 1
- 229920003303 ion-exchange polymer Polymers 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- JLESVLCTIOAHPT-UHFFFAOYSA-N mmai Chemical compound C1=C(C)C(OC)=CC2=C1CC(N)C2 JLESVLCTIOAHPT-UHFFFAOYSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000009707 neogenesis Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 229960001412 pentobarbital Drugs 0.000 description 1
- WEXRUCMBJFQVBZ-UHFFFAOYSA-N pentobarbital Chemical compound CCCC(C)C1(CC)C(=O)NC(=O)NC1=O WEXRUCMBJFQVBZ-UHFFFAOYSA-N 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 210000005084 renal tissue Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 102000014898 transaminase activity proteins Human genes 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Rheumatology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
The invention relates to the technical field of regenerative medicine, and provides application of 2-hydroxyphenyl alpha-D-glucopyranoside in preparation of a reagent for promoting blood vessel-bone formation, wherein the action concentration of the 2-hydroxyphenyl alpha-D-glucopyranoside is 200-1600 ng/mL. The 2-hydroxyphenyl alpha-D-glucopyranoside can act on human umbilical vein endothelial cells, and can promote proliferation and migration of the endothelial cells and high expression of genes related to angiogenesis; the mouse experiment proves that the 2-hydroxyphenyl alpha-D-glucopyranoside has the efficacy of promoting the repair and regeneration of the bone tissue of the osteoporosis mouse. It is shown that the 2-hydroxyphenyl alpha-D-glucopyranoside can promote skeletal vascularization and promote bone tissue repair and regeneration.
Description
Technical Field
The invention relates to the technical field of regenerative medicine, in particular to application of 2-hydroxyphenyl alpha-D-glucopyranoside in preparation of a reagent for promoting blood vessel-bone formation.
Background
Generally, the human body reaches a peak of bone mass in life before and after age 30, and bone mass begins to be slowly lost after entering middle age. Women enter the early stage of bone mass loss from 40 years old to 49 years old, and the annual loss rate is 0.4% -0.6%; the bone mass loss rate of men is relatively slow, and the bone mass loss rate is usually kept at 0.3% -0.5% from 40 years old to 64 years old to the earlier stage of bone mass loss. The female will lose about 50% of the total bone during life and about 30% of the total bone during life. Epidemiological studies have shown that: as the aging of the population becomes more serious, diseases related to bone mass loss (such as osteoporosis, fracture, bone degeneration of periodontitis and the like) become an important public health problem in China. The prevalence of bone mass loss-related diseases is highly related to advanced age, and not only is the hazard enormous, but also related medical treatment and nursing require a great deal of input of manpower, material resources and financial resources, bringing about a heavy household burden and social burden.
Studies have shown that bone is a highly vascularized tissue, while neovascularization is a key factor in bone remodeling. New blood vessels carry oxygen, nutrients, minerals, growth factors, etc. into regenerated bone tissue, and in addition, it is a pathway for inflammatory cells, bone precursor cells, to the site of injury. Angiogenesis and osteogenesis are a highly coupled process, and good blood supply is a prerequisite for bone tissue regeneration.
In the process of implant osseointegration repair, the good angiogenesis capacity can obviously improve the repair speed of bone tissues and shorten the osseointegration time. After the implant is implanted into the jawbone, the composite structure on the surface of the implant can not only create a favorable bone immune microenvironment by stimulating macrophages, but also promote proliferation and differentiation of osteoblasts/endothelial cells. Therefore, in the osseointegration process after the implant is implanted into the human body, the osseogenesis ability and the neogenesis ability of blood vessels around bone tissue are indispensable, and are two very critical parts for promoting osseointegration. In the early stages of healing of chronic periodontitis, the invasive growth of alveolar bone blood vessels is a key factor in the bone metabolic process of periodontal tissue when tissue damage and blood circulation are established, and bone blood vessels not only provide nutrients to bone tissue, but also provide oxygen necessary for bone cell activity. Bone blood vessel growth and bone metabolism balance are coupled processes, bone blood vessels transport nutrient substances necessary for promoting bone formation and transport metabolic wastes in time, and bone cells can secrete angiogenesis promoting cytokines in the process of bone formation so as to regulate blood vessel proliferation and promote vascularization.
Traditional Chinese medicines are receiving more and more attention due to their definite curative effect and low toxicity, and today, the traditional Chinese medicines have become hot spots for promoting angiogenesis. The Chinese medicinal formulas with good angiogenic effect, such as the Chinese angelica blood replenishing decoction, the peach red four-substance decoction, the single Chinese medicinal astragalus root and the like, are all prepared into medicines approved for marketing, and a large number of researches show that the Chinese medicinal materials have good curative effect on inducing angiogenesis. The traditional Chinese medicine formula has a synergistic effect, and the action mechanism is complex and is not clear through the combined action of multiple components, multiple targets and multiple ways. The traditional Chinese medicine extract is prepared by extracting the effective components to the maximum extent through a separation and purification technology, but simultaneously the non-effective components cannot be removed to the maximum extent, and often the impurities are more. The monomer is an effective component of the traditional Chinese medicine, often has higher biological activity, is easier to enter cells to exert the drug effect, has specific targets and has definite action mechanism. Therefore, the traditional Chinese medicine monomer has more remarkable effect in the aspect of inducing angiogenesis.
Disclosure of Invention
The invention aims to provide an application of 2-hydroxyphenyl alpha-D-glucopyranoside in preparing a reagent for promoting vascular-bone formation, wherein the 2-hydroxyphenyl alpha-D-glucopyranoside promotes proliferation and migration of human umbilical vein endothelial cells and high expression of genes related to vascular formation, and can promote skeletal vascularization and promote repair and regeneration of bone tissues.
In order to achieve the above object, the present invention provides the following technical solutions:
the invention provides application of 2-hydroxyphenyl alpha-D-glucopyranoside in preparing a reagent for promoting endothelial cell proliferation and migration, wherein the structural formula of the 2-hydroxyphenyl alpha-D-glucopyranoside is shown as formula I:
Preferably, the action concentration of the 2-hydroxyphenyl alpha-D-glucopyranoside is 200-1600 ng/mL.
The invention provides application of the 2-hydroxyphenyl alpha-D-glucopyranoside in promoting angiogenesis gene expression.
Preferably, the angiogenic genes include VEGF gene and TGF-beta gene.
The invention provides application of the 2-hydroxyphenyl alpha-D-glucopyranoside in preparing a reagent for promoting bone tissue repair and regeneration.
The invention provides application of the 2-hydroxyphenyl alpha-D-glucopyranoside in preparation of medicines for promoting vascular-bone formation.
Preferably, the medicine further comprises pharmaceutically acceptable auxiliary materials.
Compared with the prior art, the invention has the beneficial effects that:
The 2-hydroxyphenyl alpha-D-glucopyranoside can promote proliferation, migration and high expression of vascular endothelial cells of human umbilical vein. The experimental results of the mice show that: 2-hydroxyphenyl alpha-D-glucopyranoside is injected into an osteoporosis mouse body, does not cause the change of serum biochemical indexes (BUN, CK, ALT, AST) of the mouse, and has no chronic toxicological effect on internal organs. micro-ct scan and fluorescence double-standard results show that the density of mouse bone trabecula and the thickness of cortical bone are obviously increased, especially the thickness of cortical bone. Therefore, the 2-hydroxyphenyl alpha-D-glucopyranoside can promote skeletal vascularization and bone tissue repair and regeneration, has good application prospect, important clinical significance and commercial value, and provides a new candidate medicine for bone mass loss related diseases.
Drawings
FIG. 1 is a graph showing the effect of 2-hydroxyphenyl α -D-glucopyranoside on proliferation of endothelial cells in human umbilical vein;
FIG. 2 is a graph showing the effect of 2-hydroxyphenyl α -D-glucopyranoside on endothelial cell migration in human umbilical vein;
FIG. 3 is a graph showing the effect of 2-hydroxyphenyl α -D-glucopyranoside on the expression of a angiogenesis-related gene in human umbilical vein endothelial cells;
FIG. 4 is a graph showing the effect of 2-hydroxyphenyl α -D-glucopyranoside on biochemical indicators in mouse serum, wherein "new monomer" refers to 2-hydroxyphenyl α -D-glucopyranoside;
FIG. 5 is a graph showing the effect of 2-hydroxyphenyl α -D-glucopyranoside on the organs of mice, wherein "new monomer" refers to 2-hydroxyphenyl α -D-glucopyranoside;
FIG. 6 is an effect of 2-hydroxyphenyl α -D-glucopyranoside on mouse bone tissue, wherein "new monomer" refers to 2-hydroxyphenyl α -D-glucopyranoside;
FIG. 7 is an effect of 2-hydroxyphenyl α -D-glucopyranoside on bone deposition in mice, wherein "new monomer" refers to 2-hydroxyphenyl α -D-glucopyranoside.
Detailed Description
The invention provides application of 2-hydroxyphenyl alpha-D-glucopyranoside in preparing a reagent for promoting endothelial cell proliferation and migration, wherein the structural formula of the 2-hydroxyphenyl alpha-D-glucopyranoside is shown as formula I:
In the present invention, the concentration of 2-hydroxyphenyl α -D-glucopyranoside is 200 to 1600ng/mL, preferably 400 to 1400ng/mL, and more preferably 600 to 1200ng/mL.
The invention provides application of the 2-hydroxyphenyl alpha-D-glucopyranoside in promoting angiogenesis gene expression.
In the present invention, the angiogenesis genes include VEGF gene and TGF-beta gene.
The invention provides application of the 2-hydroxyphenyl alpha-D-glucopyranoside in preparing a reagent for promoting bone tissue repair and regeneration.
The invention provides application of the 2-hydroxyphenyl alpha-D-glucopyranoside in preparation of medicines for promoting vascular-bone formation.
In the invention, the medicine also comprises pharmaceutically acceptable auxiliary materials.
The technical solutions provided by the present invention are described in detail below with reference to examples, but they should not be construed as limiting the scope of the present invention.
Example 1
The embodiment provides a preparation method of 2-hydroxyphenyl alpha-D-glucopyranoside, which comprises the following steps:
(1) To the reaction flask was added (2S, 3R,4S,5R, 6R) -6- (acetoxymethyl) tetrahydro-2H-pyran-2, 3,4, 5-tetraacetic acid tetraester (2.5 g,6.40 mmol), catechol (2.5 g,22.70 mmol), zinc chloride (200 mg) and stirred under nitrogen at 140℃for 1.0H. The reaction was cooled, water (100 mL) was added, extracted twice with ethyl acetate (100 mL. Times.2), dried over anhydrous sodium sulfate, filtered and spin-dried, and the resulting mixture was subjected to column chromatography on silica gel (PE: EA volume ratio: 5:1) to give the target compound (2R, 3R,4S,5R, 6R) -2- (acetoxymethyl) -6- (2-hydroxyphenoxy) tetrahydro-2H-pyran-3, 4, 5-triacetate triester (1.0 g, extraction yield: 30.5%) as a white solid, which was verified to be the target compound (2R, 3R,4S,5R, 6R) -2- (acetoxymethyl) -6- (2-hydroxyphenoxy) tetrahydro-2H-pyran-3, 4, 5-triacetate triester by MS detection, MS (ESI, pos.ion) m/z:441.0[ M +H]+ ].
(2) (2R, 3R,4S,5R, 6R) -2- (Acetoxymethyl) -6- (2-hydroxyphenoxy) tetrahydro-2H-pyran-3, 4, 5-triacetate (500.0 mg,0.98 mmol), methanol (5.0 mL), sodium methoxide (16.0 mg,0.29 mmol) were added to the reaction flask at room temperature, stirred overnight at room temperature, pH was adjusted to neutral with acetic acid, filtered with ion exchange resin (50 WX 8H +) to give a filtrate, which was dried by spin-drying, and concentrated under reduced pressure to give the title compound 2-hydroxyphenyl α -D-glucopyranoside (60.0 mg, extraction yield 25.1%) as a white solid, which was verified by MS detection ,MS(ESI,neg.ion)m/z:271.0[M-H]-,1H NMR(500MHz,water-d2)：δ7.26(d,J＝7.0Hz,1H),7.04-6.96(m,3H),5.62(s,1H),3.99-3.96(m,1H),3.82-3.77(m,4H),3.55-3.52(m,1H). as the title compound 2-hydroxyphenyl α -D-glucopyranoside.
The synthetic route of the 2-hydroxyphenyl alpha-D-glucopyranoside is as follows:
Example 2
This example explores the effect of 2-hydroxyphenyl α -D-glucopyranoside on human umbilical vein endothelial cell proliferation, including the steps of:
Immortalized human umbilical vein endothelial cells (HUVECs, purchased from Bode, beijing) were cultured to the third generation, cell suspensions (2000 cells/well) were inoculated in 96-well plates, 100. Mu.L of culture broth was added, and 2-hydroxyphenyl α -D-glucopyranoside, at gradient concentrations of 0ng/mL, 100ng/mL, 200ng/mL, 400ng/mL, 800ng/mL and 1600ng/mL, respectively, was added to the culture broth (3 multiplex wells were established for each concentration of drug). The plates at each concentration were divided into three incubation times and incubated in an incubator for 12h, 24h and 48h (37 ℃,5% CO 2), respectively. To each well 10. Mu.L of CCK-8 solution was added and the plates incubated in an incubator for h. The absorbance at 450nm was measured with a microplate reader and the effective minimum concentration of 2-hydroxyphenyl α -D-glucopyranoside was selected. The results are shown in FIG. 1, and as can be seen from FIG. 1: 2-hydroxyphenyl alpha-D-glucopyranoside promotes proliferation of HUVECs and has a minimum effective concentration of 200ng/mL.
Example 3
This example explores the effect of 2-hydroxyphenyl α -D-glucopyranoside on vascular endothelial cell migration in human umbilical veins, including the steps of:
The ability of the lowest effective concentration of 2-hydroxyphenyl α -D-glucopyranoside to migrate to levels of immortalized HUVECs was assessed by in vitro scratch test. Firstly, uniformly marking transverse lines behind a 6-hole plate by using a marker pen, wherein the transverse lines are spaced by 1cm and cross through holes, and each hole at least passes through 5 lines. After HUVECs were fused to 80%, cell suspensions were collected by 0.25% trypsin digestion and inoculated into 6-well plates at 2X 10 5/well, incubated at 37℃in a 5% CO 2 incubator for 24h. After the cells are fused, the cells are scratched, and after the scratches, the cells are washed 3 times by PBS washing liquid, and the scratched cells are removed. Adding a culture medium containing 200ng/mL of 2-hydroxyphenyl alpha-D-glucopyranoside, and culturing for 12h and 24h respectively in a 5% CO 2 incubator at 37 ℃. Photographs were observed under a microscope, and migration of cells was quantified. The results are shown in FIG. 2, and can be seen from FIG. 2: the immortalized HUVECs added with 200ng/mL of 2-hydroxyphenyl alpha-D-glucopyranoside culture medium have more obvious migration trend to scratch areas, and the difference has statistical significance, which shows that the 2-hydroxyphenyl alpha-D-glucopyranoside has the capacity of promoting the migration of the HUVECs.
Example 4
The present example explores the effect of 2-hydroxyphenyl alpha-D-glucopyranoside on human umbilical vein vascular endothelial cell angiogenesis-related gene expression, including the steps of:
RNA from HUVECs was extracted using TRizol extract (Invitrogen) and reverse transcribed into cDNA using a reverse transcription kit (Apexbio, USA). SYBR green-based real-time fluorescent quantitative nucleic acid amplification assays (quantification was performed at 95℃for 30s,1 cycle; 95℃for 30s and 55℃for 30s,39 cycles) were performed using 1. Mu.L of cDNA and qPCR Mix (purchased from the following holothurian, china) to detect differential expression of the cell angiogenesis-related gene VEGF and TGF-beta. The results are shown in FIG. 3, and the results are relatively quantified by the ΔCT method, as can be seen in FIG. 3: the culture medium containing 200ng/mL of 2-hydroxyphenyl alpha-D-glucopyranoside can promote the differential expression of the angiopoiesis related genes of the immortalized HUVECs.
Example 5
The present example explores the effect of 2-hydroxyphenyl α -D-glucopyranoside on serum biochemical indicators in mouse blood, including the following steps:
12 female C57bl/6j mice of 12 weeks of age were selected and divided into 2 groups (OVX+ctrl group, OVX+2-hydroxyphenyl alpha-D-glucopyranoside group). The mice were anesthetized with sodium pentobarbital at a dose of 40mg/kg, the lower abdomen of the mice was prepared with skin, sterilized with iodophor, and iodophor was wiped off with 75% alcohol, and a 0.5cm long incision was made 0.5cm to the left of the midline of the abdomen 1cm below the ribs. The fascia and muscles are cut off, and the surgical field is passively widened. Finding white adipose tissue in the lower abdomen to pull out the body, and finding the oviduct and ovary along the ascending direction of uterus. After ligating the oviduct, the ovary and the oviduct are cut off, after bilateral excision, uterus and fat are put into the abdomen, and skin and muscle are sutured in layers. Model mice for osteoporosis were injected with 2-hydroxyphenyl α -D-glucopyranoside by tail vein for a total of 4 weeks, 3 times per week, at a dose of 5mg/kg three months after model stabilization. The control group is injected with the same amount of physiological saline, the doses of xylenol orange and calcein are 80mg/kg at the third weekend and the fourth weekend after injection, and the samples are collected after 12 hours of the last reagent injection. Serum: collecting eyeball blood, standing for 2h at 4deg.C and 3500r/min, centrifuging for 10min, and collecting serum at-80deg.C, and detecting Blood Urea Nitrogen (BUN), creatine phosphokinase (CK), alanine Aminotransferase (ALT), aspartic acid Aminotransferase (AST) in blood sample by automatic biochemical analyzer. The results are shown in FIG. 4, and as can be seen from FIG. 4: the 2-hydroxyphenyl alpha-D-glucopyranoside does not cause the change of the serum biochemical index BUN, CK, ALT, AST of the mouse, which indicates that the 2-hydroxyphenyl alpha-D-glucopyranoside does not affect the mouse.
Example 6
The present example explores the effect of 2-hydroxyphenyl α -D-glucopyranoside on the organs of mice, including the following steps:
The heart, liver, spleen, lung and kidney tissues of the mice are divided into small blocks of 0.5cm 3, and the mice are washed for 15min with flowing water. And (3) placing the sample into a full-automatic tissue dehydrator for dehydration treatment, and after dehydration, utilizing a paraffin tissue embedding machine for paraffin embedding treatment of the sample. Tissue wax blocks were sectioned at a thickness of 8 μm and attached to anti-slip glass slides for H & E staining. The results are shown in FIG. 5, and as can be seen from FIG. 5: the 2-hydroxyphenyl alpha-D-glucopyranoside does not cause obvious pathological changes such as tumor or inflammatory infiltration of important organs of mice, and has no chronic toxicological effect.
Example 7
This example explores the effect of 2-hydroxyphenyl α -D-glucopyranoside on bone tissue in mice, including the steps of:
The femur of the mouse is dissected, and after the femur is placed into 4% paraformaldehyde for 24 hours, the femur is transferred into 0.5% paraformaldehyde solution to prevent crystals from forming in bone tissues to influence sample scanning. And placing the sample in a Micro-CT special scanning tube with the tube diameter of 14mm, horizontally placing the sample, and placing the scanning tube in a Micro-CT scanning case sample tray, wherein the transverse axis of the scanning tube is perpendicular to the Micro-CT scanning axis. The scan procedure related parameters are as follows: the scan voltage was 70kVp, the scan energy power was 14W, the scan current was 200 μA, the exposure time was 300ms, the scan BH 1200mg HA/cc, the scan accuracy was 10 μm, and the scan Filter (Filter) was 0.5mmAI Filter. Later image data was reconstructed and analyzed using the chemicals 13.0 software. During femur data reconstruction, bone trabecular data analysis is carried out on all bone trabeculae of the inner layer of cortical bone, wherein the bone trabecular data is selected from the initial 1mm below a femur growth plate; cortical bone data analysis cortical bone was selected at 7-7.5 mm below the growth plate. The results are shown in FIG. 6, and the micro-ct scan results show that: after adding 2-hydroxyphenyl alpha-D-glucopyranoside, the density of the trabecular bone of the mouse is obviously increased, and the thickness of cortical bone is increased. The volume fraction (BV/TV) of the femur bone of the mice and the number (Tb.N) of the trabeculae are obviously increased, the separation degree (Tb.Sp) of the trabeculae is reduced, which indicates that the femur bone density of the mice is increased, and the trabeculae are distributed more densely.
Example 8
This example explores the effect of 2-hydroxyphenyl α -D-glucopyranoside on bone formation in mice, including the steps of:
The femur specimen of example 7 (xylenol orange and calcein were injected intraperitoneally at a dose of 80mg/kg, at 1 week intervals) was hard tissue sectioned to a slice thickness of about 15 μm. Hard tissue section was added dropwise 1:1000 volumes of diluted DAPI dye solution were used for 5min. Soaking and washing in PBS for 5min for 3 times. An anti-fluorescence quenching tablet sealer is used. And observing the red-green double-color fluorescent marks under an inverted fluorescent microscope, and counting the bone deposition rate. The results are shown in FIG. 7, and as can be seen from FIG. 7: after mice were injected with 2-hydroxyphenyl α -D-glucopyranoside, the bone formation rate (BFR/BS) and the bone mineralization deposition rate (MAR) were both significantly increased.
From the above examples, the present invention provides the use of 2-hydroxyphenyl alpha-D-glucopyranoside for preparing a reagent for promoting vascular-bone formation, wherein the 2-hydroxyphenyl alpha-D-glucopyranoside promotes proliferation and migration of human umbilical vein endothelial cells and high expression of genes related to vascular formation, and can promote skeletal vascularization and promote repair and regeneration of bone tissues.
The foregoing is merely a preferred embodiment of the present invention and it should be noted that modifications and adaptations to those skilled in the art may be made without departing from the principles of the present invention, which are intended to be comprehended within the scope of the present invention.
Claims (8)
- The application of 2-hydroxyphenyl alpha-D-glucopyranoside in preparing a medicament for treating osteoporosis is characterized in that the structural formula of the 2-hydroxyphenyl alpha-D-glucopyranoside is shown as formula I:
- 2. the use according to claim 1, wherein 2-hydroxyphenyl α -D-glucopyranoside is used for the treatment of osteoporosis by promoting endothelial cell proliferation and migration.
- 3. The use according to claim 2, characterized in that the concentration of action of said 2-hydroxyphenyl α -D-glucopyranoside is comprised between 200 and 1600ng/mL.
- 4. The use according to claim 1, wherein said 2-hydroxyphenyl α -D-glucopyranoside promotes angiogenic gene expression.
- 5. The use of claim 4, wherein the angiogenic genes comprise a VEGF gene and a TGF- β gene.
- 6. The use according to claim 1, wherein said 2-hydroxyphenyl α -D-glucopyranoside promotes bone tissue repair regeneration.
- 7. The use according to claim 1, wherein the 2-hydroxyphenyl α -D-glucopyranoside promotes vascular-bone formation.
- 8. The use according to claim 7, wherein the medicament further comprises pharmaceutically acceptable excipients.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310482744.0A CN116370485B (en) | 2023-04-28 | 2023-04-28 | Application of 2-hydroxyphenyl alpha-D-glucopyranoside in preparation of medicine for treating osteoporosis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310482744.0A CN116370485B (en) | 2023-04-28 | 2023-04-28 | Application of 2-hydroxyphenyl alpha-D-glucopyranoside in preparation of medicine for treating osteoporosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116370485A CN116370485A (en) | 2023-07-04 |
| CN116370485B true CN116370485B (en) | 2024-04-19 |
Family
ID=86973436
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310482744.0A Active CN116370485B (en) | 2023-04-28 | 2023-04-28 | Application of 2-hydroxyphenyl alpha-D-glucopyranoside in preparation of medicine for treating osteoporosis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116370485B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001001996A1 (en) * | 1999-06-29 | 2001-01-11 | University Of Western Australia | Compositions and methods for treating or preventing osteoporosis |
| KR20220151480A (en) * | 2021-05-06 | 2022-11-15 | 제주대학교 산학협력단 | Composition comprising anthocyanin isolated from an Hibiscus syriacus L. for preventing or treating bone disease |
-
2023
- 2023-04-28 CN CN202310482744.0A patent/CN116370485B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001001996A1 (en) * | 1999-06-29 | 2001-01-11 | University Of Western Australia | Compositions and methods for treating or preventing osteoporosis |
| KR20220151480A (en) * | 2021-05-06 | 2022-11-15 | 제주대학교 산학협력단 | Composition comprising anthocyanin isolated from an Hibiscus syriacus L. for preventing or treating bone disease |
Non-Patent Citations (1)
| Title |
|---|
| 苷类化合物研究Ⅱ――熊果苷和天麻苷类似物的NMR研究;李立璞等;《波谱学杂志》;19890228;6(01);全文 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116370485A (en) | 2023-07-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108938618A (en) | Delay compound and its application of human mesenchymal stem cell aging | |
| CN106676177A (en) | Application of lnc (long non-coding) RNA lnc-DIF | |
| WO2017146309A1 (en) | Novel use of eupatilin as pharmaceutical composition for preventing and treating fibrosis by using epithelial-mesenchymal transition inhibitory activity thereof | |
| CN113151177B (en) | Breast or breast cancer tissue acellular matrix and preparation method and application thereof | |
| CN116370485B (en) | Application of 2-hydroxyphenyl alpha-D-glucopyranoside in preparation of medicine for treating osteoporosis | |
| Shyu et al. | Hyperbaric oxygen induces placental growth factor expression in bone marrow-derived mesenchymal stem cells | |
| CN111870639A (en) | Application of Tibetan medicine scindapsus aureus in preparing medicine for treating atherosclerosis | |
| WO2020030091A1 (en) | Drug used for treating tissue necrosis or for improving cardiac function | |
| CN107496428B (en) | Calycosin derivative promotes the application in endothelial cell proliferation drug in preparation | |
| CN110292629A (en) | Application of the Hexokinase 1 in anti-aging | |
| CN110511931A (en) | Sal-miR-1 and Sal-miR-3 and its purposes in medicine preparation | |
| CN108714149A (en) | Purposes of the garden burnet active constituent in preparing anti-tumor drug | |
| CN113648306A (en) | Application of bergamottin in preventing or treating osteoporosis and/or bone loss | |
| CN101230331A (en) | Use of baicalin in promoting vitro directional differentiation of mesenchymal stem cells and method thereof | |
| CN113786397B (en) | Application of curcuma zedoary extract in preparation of medicines for treating breast cancer bone metastasis | |
| JP7402524B2 (en) | Use of AMD3100 in the manufacture of medicaments for treating and/or preventing cachexia, and pharmaceutical compositions comprising AMD3100 | |
| CN113908148B (en) | Application of nobiletin in preparation of anti-cholangiocarcinoma drugs | |
| CN114452280B (en) | Application of atractylone in preparation of glioma treatment drug | |
| CN116874545B (en) | Coupling medicine, preparation method thereof and application of coupling medicine in preparation of medicine for treating rheumatoid arthritis synovium | |
| CN101215563A (en) | KDR siRNA and application thereof | |
| CN115737671A (en) | Application of heparin dodecasaccharide in preparing medicine for treating diseases caused by cell hypoxia injury | |
| CN107243006A (en) | Applications of the AMD3100 in the medicine for preparing treatment and/or prevention dyscrasia | |
| CN1857739A (en) | Tumor model and method | |
| Abouleisa et al. | Transient Cell Cycle Induction in Cardiomyocytes to Treat Ischemic Heart Failure | |
| CN117883461A (en) | Application of glycyrrhetinic acid monoglucuronide in resisting pulmonary fibrosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |